Uncomplicated Urinary Tract Infection Market – Opportunities, Share, Growth and Competitive Analysis and Forecast 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Is The Uncomplicated Urinary Tract Infection Market Expected To Grow In Terms Of Size?
Over the past few years, the market for uncomplicated urinary tract infections has experienced substantial growth. Its size is expected to increase from $10.24 billion in 2024 to $10.95 billion in 2025, marking a compound annual growth rate (CAGR) of 6.9%. This growth during the previous period is a result of factors such as an increase in renal failure cases, a rise in bladder cancer instances, a surge in chronic kidney disease incidences, expanded use of urinary catheters, and a widespread prevalence of diabetes.
The market for uncomplicated urinary tract infections is predicted to experience substantial growth in the coming years, expanding to a value of $14.15 billion by 2029, with a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this growth in the forecast period include an increase in bacterial infections, a rising aging population, increased sexual activity, a surge in reported urinary tract infection instances, and heightened use of contraceptives. Foreseen trends during this period incorporate the progression of telemedicine, enhancements in telehealth solutions, the creation of new drugs, progress in urinary tract infection therapies, and advancements in research and development.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23550&type=smp
What Are The Primary Factors Supporting The Uncomplicated Urinary Tract Infection Market Expansion?
The escalating occurrences of chronic kidney diseases are set to invigorate the uncomplicated urinary tract infection market in the future. When the kidneys progressively lose efficiency over a prolonged duration, a condition known as Chronic Kidney Disease (CKD) develops which results in waste and fluid accumulation in the body. The rise in chronic kidney diseases is linked to the surging prevalence of diabetes, as sustained high blood sugar levels can harm the kidneys and obstruct their waste filtering ability. As the chronic kidney disease impairs the immune system, it leaves individuals more vulnerable to urinary tract infections. Inefficient kidney function causes urine retention which fosters bacterial growth. For example, data from Kidney Research UK, a charity based in the UK, showed that the amount of adults requiring kidney transplants due to chronic kidney disease in the United Kingdom spiked from 2,863 transplants in 2021 to 2,976 in June 2023. Hence, the surge in chronic kidney disease occurrences is set to fuel the uncomplicated urinary tract infection market.
Which Segmentation Categories Are Highlighted In The Uncomplicated Urinary Tract Infection Market Analysis?
The uncomplicated urinary tract infectionmarket covered in this report is segmented –
1) By Test Type: Urinalysis; Urine Cultures; Susceptibility Testing
2) By Drug: Penicillin And Combinations; Quinolones; Cephalosporin; Azoles And Amphotericin B; Nitrofurans; Other Drugs
3) By End-Users: Hospitals; Diagnostic Labs; Research Institutes
Subsegments:
1) By Urinalysis: Dipstick Tests; Microscopic Examination; Automated Urinalysis
2) By Urine Cultures: Agar Plate Culture; Broth Culture; Chromogenic Media
3) By Susceptibility Testing: Disk Diffusion Method; Automated Susceptibility Testing; Molecular Susceptibility Testing
Which Market Trends Are Expected To Define The Future Of The Uncomplicated Urinary Tract Infection Market?
Leading firms in the uncomplicated urinary tract infection (UTI) market are concentrating on the creation of antibiotics to boost the efficacy of treatment and battle bacteria that are resistant to antibiotics. Antibiotics serve as treatments for bacterial infections by eliminating or stunting the growth of bacteria in the human body. For illustration, the US-based Food and Drug Administration, a federal agency, gave its approval to Pivya (pivmecillinam) tablets in April 2024 for the treatment of uncomplicated urinary tract infections in adult females. Pivmecillinam, a prodrug, is transformed into mecillinam, a type of beta-lactam antibiotic that aims at Gram-negative bacteria by forestalling the synthesis of bacterial cell walls; this tablet is specifically designed for uncomplicated urinary tract infection caused by susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
Which Organizations Are At The Forefront Of The Uncomplicated Urinary Tract Infection Market?
Major companies operating in the uncomplicated urinary tract infection market are Cardinal Health, Pfizer Inc., Bayer AG, AstraZeneca plc, GSK plc, Eli Lilly and Company, Siemens AG, Strykar Healthcare, John Hopkins Medicine, Shionogi & Co. Ltd., Sysmex Corporation, Bio-Rad Laboratories Inc, Cipla Inc., UTILITY therapeutics Ltd, Orchid Pharma Limited, ACON Labs, Sonika Lifesciences, Emergency Care BC, EB Medicine, Iterum Therapeutics PLC
Access The Complete Report Here:
Which Geographic Regions Are Creating Strong Demand In The Uncomplicated Urinary Tract Infection Market?
North America was the largest region in the uncomplicated urinary tract infection market in 2024. The regions covered in the uncomplicated urinary tract infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=23550&type=smp
Browse Through More Reports Similar to the Global Uncomplicated Urinary Tract Infection Market 2025, By The Business Research Company
Pharmaceutical Drugs And Biologics Logistics Market 2025
Urinary Incontinence And Pelvic Organ Prolapse Devices And Equipment Global Market Report 2025
Urinary Stone Treatment Devices And Equipment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
